Advaxis, Inc. Announces Two Abstracts Accepted for Presentation at SITC Annual Meeting
8/23/2012 10:11:20 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts describing research with Advaxis Lm-LLO immunotherapies have been selected for oral and poster presentations at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting, October 26-28, 2012 at the Bethesda North Marriott Hotel & Conference Center in North Bethesda, MD.
comments powered by